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BACKGROUND
The safety of long-acting β2-agonists (LABAs) remains controver-
sial in asthma, particularly in children, which led regulators to
contraindicate LABAs as a single agent in asthma treatment.1
Current evidence regarding the safety of LABAs in combination
with inhaled corticosteroids (ICs), based on meta-analyses of
randomised clinical trials (RCTs), is less consistent. Recently
updated meta-analyses for formoterol and salmeterol failed to
reassure on safety.2,3 Despite the absence of evidence of serious
risk with LABAs associated with ICs, the precision of results was
low owing to infrequent outcomes. Furthermore, RCTs include
highly selected populations, and they are not properly designed
to assess infrequent and/or long-term adverse events in actual
conditions of drug use.4
Evidence is also limited in the observational context. A recent
systematic review assessing the risk of LABAs associated with ICs,
compared with ICs alone, did not indicate any increased risk for
emergency visits or hospital admissions.5 However, no reliable
conclusions could be drawn neither in children, nor on potential
differences between LABAs associated with ICs, in ﬁxed-dose
combinations, and in two separate canisters, due to the lack of
published data for these speciﬁc issues. This review also highlighted
the scarcity of prospective studies and the lack of data on drug
adherence. Most of the observational studies were based on claims
databases, providing only a partial assessment of drug exposure.
There is an evidence gap, as detailed and valid exposure data are
needed. For instance, irregular use of ICs in persistent asthma is a
well-known source of exacerbations.6 Thus, there is a need to
explore potential risks associated with LABAs in real life, with more
extensive assessments of patterns of use, including ICs concomitant
therapy, asthma control and exacerbations over time.
AIMS
The ASTRO-LAB project aims to provide new evidence about the
safety of LABAs in children and adults in routine clinical care. Its
main objective is to investigate with prospective data whether
asthma patients receiving LABAs are at a higher risk of severe
asthma exacerbations (SAEx), taking into account baseline differ-
ences in severity. Potential variations of respective drug exposures
to LABAs and ICs over time, using complementary data sources will
also be investigated. In addition, it will be veriﬁed whether
differential adherence to LABAs and to ICs is a possible mechanism
of increased risk of SAEx and other asthma outcomes in patients
using these drugs in two separate canisters. A key question that
ASTRO-LAB aims to explore is whether the potential LABA-
associated risk can be explained by suboptimal adherence to ICs.
METHODS
ASTRO-LAB is a 24-month prospective observational study in asthma,
conducted in France and in the United Kingdom (UK).
Participants
ASTRO-LAB will include persistent asthma patients treated in primary care,
equally distributed between children (6–17 years) and adults (18–40 years).
Inclusion of patients will be performed between May 2013 and February
2015 in the three steps described hereunder (Figure 1).
Patient pre-selection. British patients aged 6–40 years with at least one
LABA and/or IC prescription during the past 12 months will be pre-selected
from The Health Improvement Network, which is a collection of pseudo-
anonymised electronic primary care medical records7 collected in approxi-
mately 550 general practices in the UK, with 3.6 million active patients.
In France, more than 700 general practitioners will perform a preliminary
selection of asthma patients aged 6–40 years, with at least two
prescriptions of LABAs and/or ICs during the past 12 months, regardless
of associations with other controllers. General practitioners will record all
asthma-related prescriptions during the past 12 months. A similar pre-
selection will be conducted in community pharmacies: pharmacists will
record all asthma-related prescriptions available during this time interval
for patients aged 6–40 years, with at least one dispensing of LABAs and/or
ICs and two pharmacy visits during these past 12 months.
Patient eligibility. From the pre-selection database, the research team will
select, in both countries, patients on the basis of an additional inclusion
criterion, i.e., ⩾ 6 months of prescribed coverage of one of the following
therapy patterns during the past 12 months: ICs without LABAs, LABAs
without ICs, LABAs and ICs as separate inhalers (LABAs+ICs) or ﬁxed-dose
combinations (ﬁgures available in the Supplementary Information). No
change of therapy pattern will be allowed during the last 12 months.
The following exclusion criteria will be checked in pre-selection
databases (for the UK) or during enrolment visit by a general practitioner
or a pharmacist (for France): chronic oral corticosteroid use (⩾15
consecutive days during the past 3 months), history of omalizumab
therapy and/or any other concomitant respiratory disease (chronic
obstructive pulmonary disease, cystic ﬁbrosis, pulmonary ﬁbrosis, bronch-
iectasis and tuberculosis). In case of SAEx within 2 months before inclusion,
patients will be re-contacted 4 months later, so that they will be free of
recent SAEx when entering the cohort.
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Patients’ enrolment. In France, general practitioners and pharmacists will
invite eligible patients to participate in the study during a general
practitioner or pharmacy visit. In the UK, practices will forward postal
invitation packs to eligible patients, who will be invited to contact the
logistic centre by phone or online. A consent acknowledgement will be
collected before any data collection.
Data collection
Data collection schedule for patient-, caregiver- and health care profes-
sionals (HCP)-reported data is summarised in Figure 2.
Patient-reported data
Computerised-assisted telephone interviews and text messages:
Trained interviewers will administer computerised-assisted telephone
interviews (CATIs) to patients aged 12–40 years (parents/caregivers of
patients aged 6–11 years) immediately after inclusion and every 4 months,
to assess asthma control, asthma medication used during the past
4 months and SAEx occurrence. If a SAEx is reported, the asthma control-
and medication-related questions will be repeated for the period before
the SAEx, followed by additional questions (triggers, management).
Patients will also receive monthly text messages inquiring about potential
new SAEx; a positive answer will be followed by an additional CATI
including the above-mentioned SAEx-related questions.
Online surveys: Patients and/or parents/caregivers will be requested to
complete online surveys (adapted to age-speciﬁc requirements) at
12-month intervals on determinants of medication adherence, self-
monitoring of symptoms, triggers and exacerbations management, quality
of inhaler technique, quality of life, demographic and other background
characteristics.
Figure 1. Study ﬂowchart for patient enrolment and follow-up.
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HCP-reported data. HCPs will complete online surveys on their routine
asthma care and determinants of adherence support.
Electronic medical records/claims data. The Health Improvement Network
data will be available in the UK, whereas reﬁll and hospitalisation data will
be obtained from the National Health Insurance System (SNIIRAM) in
France.
Measures
We present the main characteristics of the measures relevant to the
primary research question regarding the safety of LABAs.
Outcomes. The primary outcome will be the occurrence of SAEx,8–10
operationalised as occurrence of patient-reported courses of oral
corticosteroids (⩾3- day duration), unscheduled asthma-related medical
contacts, emergency room visits, hospital admissions and death.
The secondary outcomes will be asthma control, measured with
validated questionnaires—symptoms only Asthma Control Questionnaire
(ACQ-5)11 and the Royal College of Physicians three questions,12,13 as well
as the ﬁve-level European Quality of Life—5 Dimensions (http://www.
euroqol.org/about-eq-5d/publications.html (25 November 2013)). For the
latter, French and UK valuation set will be applied to estimate utilities in
French and English participants, respectively.
Medication use and adherence. Medication use will be assessed via CATIs
for each daily inhaled medication separately, with questions referring to
different time intervals and behaviours: number of doses used the day
before the interview, number of days with 0% and 100% adherence during
the previous 7 days, number of days of non-use during the previous
4 weeks, treatment interruptions longer than a week in the previous
4 months, and medication overuse (for a speciﬁc time interval or
occasional) in the previous 4 months. Patient/caregiver-reported drug
exposure and adherence will be computed via algorithms developed in
preliminary analyses.
Therapy patterns, sample size and planned analyses
Studied exposure groups will be based on four initial therapy patterns.
Preliminary results on pre-selected populations revealed that, for instance,
only 2.4% of patients were prescribed LABAs without ICs in France, and
virtually none in the UK. Given these low frequencies, patients under LABA
monotherapy would be merged with those receiving ICs and LABAs as
separate canisters, after having preliminarily veriﬁed their comparability.
Hence, three groups have been considered for sample size power
computation: LABAs with ICs in separate canisters or in monotherapy,
LABA/ICs ﬁxed-dose combinations and ICs without LABAs.
Sample size. Sample size computation for required power was based on
differences in binomial proportions of SAEx between the reference ICs
without LABAs group and LABAs with ICs in separate canisters or in
monotherapy group. The hypothesis for the outcome frequency (24%) was
based on asthma-related oral corticosteroid courses reported by patients
during a 12-month period in a pharmacy-based study conducted in 2007
in ICs-treated patients.14 This hypothesis is conservative, as it may
underestimate the true frequency of SAEx, which not only consider oral
corticosteroid courses but also hospitalisations, unplanned medical
contacts and death. Sample size calculations were based on the expected
1.3-fold higher frequency SAEx between the ICs without LABAs group and
the other two groups. Considering a bilateral approach and balanced
counts between groups, it was calculated that a total of 2,200 patients
would be required given a statistical power of 80%, at a signiﬁcance level
of 5%, with a potential 20% loss to follow-up.
Planned analyses
Safety analyses: Between-group comparisons. As ﬁrst approach, the time
to the occurrence of the ﬁrst SAEx will be compared between the initial
exposure groups (ICs without LABAs group as reference) with survival
analyses (Kaplan–Meier, Cox Model). The total number of SAEx per patient
during a 12-month period will be also compared using Poisson regression.
Cohort analyses with time-dependent variables. Patients’ actual exposure
to LABAs and ICs may change over follow-up owing to the prescriber or
patient. In these analyses, such changes will be taken into account. Time-
dependent variables, reﬂecting LABAs or ICs exposure over follow-up, will
be constructed. The association between exposure to LABAs over time and
the occurrence of SAEx will be investigated, after adjusting in particular for
concomitant exposure to ICs. Survival analyses and hierarchical long-
itudinal models will be applied. Different markers of drug exposure and
adherence will be successively explored.
Case–crossover study and nested case–control study approaches. As in
a case–crossover design patients are their own controls, LABAs and ICs
studied drug exposure patterns occurring just before a SAEx (case period)
will be compared with those observed during a preceding regular CATI
with no SAEx reported (control period), thus eliminating any potential
inﬂuence of patients ﬁxed characteristics. A nested case–control study
approach will be also considered.
Adjustment for asthma baseline severity. Analyses will be adjusted for the
different markers of asthma baseline severity, as it is a potential
confounding factor when assessing LABA-related risk, except for the
case–crossover approach.
Complementary analyses will be considered with the French patients,
using claims data.
Adherence analyses: The relationships between medication adherence
determinants and behaviours and asthma-related outcomes will be
investigated based on a theoretical model of asthma management.
Figure 2. Summary of patient- and physician-reported data at inclusion and during follow-up.
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These analyses will further examine the hypothesis that LABA risk in
asthma may be partly owing to suboptimal adherence to ICs, with initial
symptoms masked by concomitant LABA use, leading to severe and
sudden SAEx. Moreover, they also aim to identify important
and changeable causes of nonadherence from a patient, caregiver and
HCP perspective, with a view to improving adherence support in
primary care.
Ethics
ASTRO-LAB study has been approved by Ethics and Regulatory Boards in
both countries.
DISCUSSION
ASTRO-LAB presents several innovative aspects that will allow a
unique perspective on LABA safety and asthma management, in
real-life conditions. Data will be collected from complementary
sources to assess patients’ drug exposure. This will allow assessing
more elaborated markers of drug exposure and adherence to
check the robustness of our ﬁndings.
The direct assessment of patients’ adherence to therapy,
including potential changes over time, will enable us to
distinguish the confounding role of inadequate adherence to ICs
from LABA-speciﬁc risk, as differential adherence between LABAs
and ICs may contribute to the occurrence of SAEx for patients
receiving both classes in separate canisters.
Methodological limitations and practical difﬁculties must be
acknowledged. The scarcity of patients prescribed LABAs in
monotherapy may prevent any reliable conclusion for this non-
recommended therapy pattern.6,15 Pre-selection process between
countries will differ: pre-existing prescribing database in the UK
versus an ad hoc prescription register collected by physicians
themselves purposely for the study. This difference is owing to
practical access to existing prescribing data (possible in the UK
only, in the context of ASTRO-LAB). Nevertheless, the same
inclusion/exclusion criteria will be eventually applied to all
patients in both countries. A potential bias inherent to prospective
studies will be that patients’ interaction with ﬁeld study
procedures (for example, questionnaires and CATIs) may modify
their behaviours and beliefs regarding medication intake. None-
theless, this potential bias will inﬂuence all treatment groups
equally.
Practical difﬁculties have to be addressed in this multifaceted
project. Different national regulatory requirements and health care
systems between France and the United Kingdom compelled us to
consider speciﬁc recruitment processes for each country, while
attempting to maintain the two processes as similar as possible to
minimise bias.
Given its unique perspective on asthma care, ASTRO-LAB will
provide new information on LABA safety of substantial interest to
regulators, HCPs, patients and the scientiﬁc community. Moreover,
developing new methods of assessing drug exposure and
adherence will make a valuable contribution beyond the ﬁeld of
asthma care. The investigation of multifaceted insight into asthma
management in two different medical systems may be informative
for the improvement of asthma care.
Further information can be found in the Supplementary
Information.
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